atenolol has been researched along with Day Blindness in 3 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodenas, M | 1 |
| Kumar, S | 1 |
| Freund, KB | 1 |
| Moallem, J | 1 |
| Matthews, DR | 1 |
| Stratton, IM | 1 |
| Aldington, SJ | 1 |
| Holman, RR | 1 |
| Kohner, EM | 1 |
| Kumar, KL | 1 |
| Cooney, TG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema[NCT02718547] | 25 participants (Anticipated) | Interventional | 2017-03-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for atenolol and Day Blindness
| Article | Year |
|---|---|
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Bloo | 2004 |
2 other studies available for atenolol and Day Blindness
| Article | Year |
|---|---|
Retinitis preceding systemic lupus erythematosus in absence of anti-phospholipid antibodies.
Topics: Adolescent; Antibodies, Antiphospholipid; Atenolol; Cyclophosphamide; Diagnosis, Differential; Drug | 2012 |
Visual symptoms after atenolol therapy for migraine.
Topics: Adult; Atenolol; Female; Humans; Migraine Disorders; Vision Disorders | 1990 |